Genespire raises €46.6 million (~$52 million) in a Series B round to advance its first pediatric in-vivo gene therapy into the clinic by Harry Fowler | Sep 25, 2024 | News
Genespire Presents Positive Preclinical Proof of Concept Data at the ASGCT Annual Meeting by Harry Fowler | May 9, 2024 | News
Genespire appoints Jörn Aldag as Chairman of the Board of Directors by Harry Fowler | Jul 2, 2020 | News
Genespire and the San Raffaele Telethon Institute for Gene Therapy announce publication in Nature Biotechnology on enhanced gene editing technique in hematopoietic stem cells by Harry Fowler | Jun 2, 2020 | News
